From glucose to a larger question
SURPASS, SURMOUNT and approvals · 2021–2023
Was this a glucose story or a weight story?
Subject One brings his glucose notebook back to the desk. A second folder, WEIGHT MANAGEMENT, is waiting. “Is that the same exam?” “Different question,” says Doctide. “Different people. More evidence.”
What changes here
Both questions were tested—but in distinct trials and populations, leading to separate product approvals. [2] [4]
Read the study details & dates
SURPASS-2
A 40-week trial enrolled 1,879 people with type 2 diabetes and compared tirzepatide with semaglutide 1 mg. HbA1c was the primary outcome. This was not a comparison with obesity-dose semaglutide. Tirzepatide produced greater average HbA1c reductions than the semaglutide comparator. [1]
Mounjaro’s first US approval
FDA approved Mounjaro for adults with type 2 diabetes. Its review drew on multiple trials, not one volunteer’s experience. [2]
SURMOUNT-1
This 72-week trial studied 2,539 adults with obesity, or overweight plus a weight-related complication, without diabetes. Mean weight reduction ranged from 15.0% to 20.9% across tirzepatide arms, versus 3.1% with placebo under the treatment-regimen analysis. Adverse events caused some participants to discontinue. [3]
Zepbound’s weight-management approval
FDA approved Zepbound for chronic weight management in eligible adults alongside diet and physical activity. [4]
What this does not establish
Trial results belong to the studied populations. A diabetes comparator trial and an obesity placebo-controlled trial cannot be treated as the same contest.
Original sources
- SURPASS-2 primary publication
- FDA Mounjaro Drug Trials Snapshot
- SURMOUNT-1 primary publication
- FDA Zepbound weight-management approval
Sources reviewed 2026-10-11. Study and publication dates are stated separately where known.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story